Approval · Notice of Compliance 13648 · 2012
RIASTAP: Notice of Compliance 13648
Issued September 13, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13648
- Date
- September 13, 2012
- Company
- Csl Behring Canada IncOttawa, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
- Therapeutic class
- Coagulation Factor I
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RIASTAP | 02393352 | Marketed |
Medicinal ingredients
- FIBRINOGEN (HUMAN) 1,000 MG per VIAL